

GAAP Reconciliations

Reconciliation of Adjusted Operating Income and Adjusted EBITDA

(in millions)	Three-Months Ended December 31,		Twelve-Months Ended December 31,	
	2007	2006	2007	2006
Operating income, as reported	\$ 32.3	\$ 18.5	\$ 94.8	\$ 78.1
(Subtract) Add: Receivable reserve	(0.1)	--	8.1	--
(Subtract) Add: Acquisition related incentive	(1.5)	3.5	(1.5)	3.5
Add: Impairment loss on marketable securities	0.8	--	0.8	--
Adjusted operating income	31.5	22.0	102.2	81.6
Add: Depreciation	5.0	4.0	18.2	15.1
Add: Amortization	3.6	1.4	10.9	5.6
Adjusted EBITDA *	\$ 40.1	\$ 27.4	\$ 131.3	\$ 102.3

* before minority interest in income of subsidiary and income from equity investments

Reconciliation of Adjusted Net Income from Continuing Operations and Adjusted Diluted EPS from Continuing Operations including Equity Compensation Expense

(in millions)	Three-Months Ended December 31,		Twelve-Months Ended December 31,	
	2007	2006	2007	2006
Net income from Continuing Operations	\$ 15.5	\$ 9.0	\$ 47.2	\$ 49.2
Add: Receivable reserve, net of taxes	--	--	4.8	--
Add: Acquisition related incentive, net of taxes	(0.9)	2.1	(0.9)	2.1
Add: Impairment loss on marketable securities, net of taxes	0.5	--	0.5	--
Add (Subtract): Derivative interest, net of taxes	0.2	0.2	0.7	(1.2)
Deduct: Tax benefit	--	--	(1.0)	(9.1)
Adjusted Net income from Continuing Operations	\$15.3	\$11.3	\$51.3	\$41.0
Diluted Shares Outstanding	32.9	30.6	32.3	30.1
Adjusted Diluted EPS from Continuing Operations	\$0.47	\$0.37	\$1.59	\$1.37*

* The sum of the adjusted net earnings per share do not add up to the twelve-months amount due to rounding and because the quarterly calculations are based on varying number of shares outstanding.

Reconciliation of Segment Operating Income

(in millions)	inVentiv Clinical				inVentiv Commercial				inVentiv Communications				inVentiv Patient Outcomes			
	Q407	Q406	YTD07	YTD06	Q407	Q406	YTD07	YTD06	Q407	Q406	YTD07	YTD06	Q407	Q406	YTD07	YTD06
Operating income, as reported	\$4.7	\$2.8	\$14.2	\$11.6	\$12.7	\$12.9	\$38.2	\$45.8	\$14.1	\$3.6	\$42.0	\$26.2	\$6.1	\$3.2	\$17.6	\$7.2
Add: Equity compensation expense	--	0.3	1.1	1.1	0.8	0.6	4.3	3.3	0.3	0.1	1.3	0.7	0.1	0.3	0.5	0.6
Add: Acquisition-related incentive	--	--	--	--	--	--	--	--	(1.5)	3.5	(1.5)	3.5	--	--	--	--
Add: Receivable reserve	--	--	--	--	0.1	--	8.1	--	--	--	--	--	--	--	--	--
Adjusted Operating Income	\$4.7	\$3.1	\$15.3	\$12.7	\$13.6	\$13.5	\$50.6	\$49.1	\$12.9	\$7.2	\$41.8	\$30.4	\$6.2	\$3.5	\$18.1	\$7.8

Proforma Annual Compound Growth Rate ("CAGR") on a Net Revenue Basis

	YR 2003 to YR2007	
	Total	inVentiv Commercial**
CAGR%, as reported	41%	12%
Less: Acquisition CAGR%	23%	3%
CAGR%, proforma	18%	9%

** inVentiv Communications, inVentiv Clinical and inVentiv Patient Outcomes were not part of the company in 2003 and thus the GAAP reconciliations are not meaningful for those segments.

Proforma Growth Rate on a Net Revenue Basis

	YTD07 vs YTD06
	Total
Growth%, as reported	26%
Less: Acquisition Growth%	13%
Growth%, proforma	13%

Guidance

	2008 E
	Adjusted EPS
Less: Derivative interest, net of taxes	(.02)
GAAP EPS	\$1.78 - \$1.88

